Agios (NASDAQ: AGIO) director exercises RSUs and gains new equity awards

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

AGIOS PHARMACEUTICALS director Rahul D. Ballal reported equity compensation transactions. He exercised 2,816 restricted stock units into common stock and, after these transactions, directly holds 15,230 common shares.

On the same date, he received 14,950 stock options at an exercise price of $34.16 per share, expiring on June 18, 2036, and 2,927 new restricted stock units. Footnotes state the exercised RSUs were granted on June 18, 2025 and vested on June 18, 2026, while the new RSUs and options were granted on June 18, 2026 and will vest in full on June 18, 2027.

Insider Trade Summary

2,816 shares exercised/converted

Mixed 4 txns

Insider Ballal Rahul D.

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted stock units	2,816	$0.00	--
Grant/Award	Restricted stock units	2,927	$0.00	--
Grant/Award	Stock options (right to buy)	14,950	$0.00	--
Exercise	Common stock	2,816	$0.00	--

Holdings After Transaction: Restricted stock units — 0 shares (Direct, null); Stock options (right to buy) — 14,950 shares (Direct, null); Common stock — 15,230 shares (Direct, null)

Footnotes (1)

Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.

Key Figures

RSUs exercised into common stock: 2,816 shares Common shares after transactions: 15,230 shares New stock options granted: 14,950 options at $34.16 +2 more

5 metrics

RSUs exercised into common stock 2,816 shares Converted to common stock on June 18, 2026

Common shares after transactions 15,230 shares Direct holdings following June 18, 2026 activity

New stock options granted 14,950 options at $34.16 Granted June 18, 2026; expire June 18, 2036

New RSUs granted 2,927 units Granted June 18, 2026; vest June 18, 2027

RSUs previously granted 2,816 units Granted June 18, 2025; vested June 18, 2026

Key Terms

Restricted stock units, Stock options (right to buy), Exercise or conversion of derivative security, Grant, award, or other acquisition

4 terms

Restricted stock units financial

"Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock options (right to buy) financial

"These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027."

Exercise or conversion of derivative security financial

"transaction_code_description: Exercise or conversion of derivative security"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/23/2026 - 05:25 PM Accepted by SEC EDGAR 06/23/2026 - 05:25 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ballal Rahul D.

(Last)

(First)

(Middle)

C/O AGIOS PHARMACEUTICALS, INC.

88 SIDNEY STREET

(Street)

CAMBRIDGE

MASSACHUSETTS

02139

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
AGIOS PHARMACEUTICALS, INC. [ AGIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock	06/18/2026		M		2,816	A	$0	15,230	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted stock units	⁽¹⁾	06/18/2026		M			2,816	⁽²⁾	⁽²⁾	Common stock	2,816	$0	0	D
Restricted stock units	⁽¹⁾	06/18/2026		A		2,927		⁽³⁾	⁽³⁾	Common stock	2,927	$0	2,927	D
Stock options (right to buy)	$34.16	06/18/2026		A		14,950		⁽⁴⁾	06/18/2036	Common stock	14,950	$0	14,950	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

2. The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

3. The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

4. These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.

Remarks:

	/s/ William Cook, as attorney-in-fact for Rahul Ballal	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did AGIO director Rahul D. Ballal report?

Rahul D. Ballal reported exercising 2,816 restricted stock units into common stock and receiving new equity awards. These awards included 14,950 stock options and 2,927 restricted stock units, all tied to Agios Pharmaceuticals’ common stock and structured as compensation rather than open-market trades.

How many AGIOS PHARMACEUTICALS shares does Rahul D. Ballal hold after these Form 4 transactions?

After exercising restricted stock units, Rahul D. Ballal directly holds 15,230 shares of Agios common stock. This total reflects the 2,816 shares received from RSU conversion on June 18, 2026, combined with his prior holdings, as reported in the Form 4 filing.

What are the terms of the new AGIO stock options granted to Rahul D. Ballal?

Rahul D. Ballal received 14,950 stock options with an exercise price of $34.16 per share. Footnotes state the options were granted on June 18, 2026, vest 100% on June 18, 2027, and expire on June 18, 2036, if not earlier exercised or forfeited.

What restricted stock unit activity did the AGIO Form 4 disclose?

The filing shows 2,816 restricted stock units granted June 18, 2025 vested and were converted into common shares. It also reports a new grant of 2,927 restricted stock units on June 18, 2026 that will vest in full on June 18, 2027, subject to continued conditions.

Did Rahul D. Ballal sell any AGIOS PHARMACEUTICALS shares in this Form 4?

The Form 4 reports only acquisitions and exercises, with no dispositions. Transactions include an RSU conversion into 2,816 common shares and grants of 14,950 stock options plus 2,927 restricted stock units, indicating compensation-related activity rather than open-market sales.

When will the newly granted AGIO restricted stock units and options vest for Rahul D. Ballal?

Footnotes explain that both the 2,927 restricted stock units and the 14,950 stock options granted on June 18, 2026 will vest in full on June 18, 2027. Vested shares from RSUs will be delivered within three business days after the vesting date.